HER2-low metastatic urothelial carcinoma with liver metastases responding to antibody–drug conjugate therapy: a case report
While HER2-targeted antibody-drug conjugates (ADCs) have shown efficacy in advanced bladder cancer with liver metastases (LM), current guidelines focus on HER2-high (IHC 3+/2+) disease. This case reports a sustained remission in HER2-low (IHC 1+) metastatic urothelial carcinoma (UC) with hepatic dissemination usi...